Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUPKYNIS vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of lupus nephritis in combination with a background immunosuppressive therapy
Management of mild to moderate pain,Reduction of fever
23.7 mg orally twice daily with food.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life approximately 30 hours; supports once-daily dosing; steady-state reached by day 4.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily metabolized by CYP3A4; minor contribution from CYP3A5.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily hepatic metabolism; <1% excreted unchanged in urine; approximately 66% of total radioactivity recovered in feces (mainly metabolites) and 22% in urine (mainly metabolites).
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Greater than 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
Apparent Vd/F ~24 L (approximately 0.34 L/kg assuming 70 kg); indicates distribution into tissues.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability approximately 35% (range 20–50%) under fasting conditions; high-fat meal reduces Cmax and AUC by about 50%.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for GFR ≥30 m L/min. Avoid use in severe renal impairment (GFR <30 m L/min) due to lack of data.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 15.8 mg orally twice daily. Child-Pugh Class C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients; no approved dose.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment required; monitor renal function due to age-related decline.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Increased risk of infection and lymphoma; increased risk of nephrotoxicity and hypertension; increased risk of neurotoxicity.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Nephrotoxicity and hypertension require regular monitoring. Neurotoxicity including posterior reversible encephalopathy syndrome (PRES). Increased susceptibility to infections including opportunistic infections. Malignancies including lymphoma. Monitor for Epstein-Barr virus serology. Use with caution with CYP3A4 inhibitors and inducers. Avoid live vaccines.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Concurrent use with chronic immunosuppressive therapies other than mycophenolate mofetil (MMF) or mycophenolic acid (MPA). Known hypersensitivity to voclosporin or any component of the formulation.
Hypersensitivity to acetaminophen or any component of the formulation
Avoid grapefruit and grapefruit juice as they increase voclosporin exposure. No other specific food interactions are known.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during organogenesis resulted in increased embryofetal mortality and reduced fetal weight at maternally toxic doses. There are no adequate human studies. Avoid use during pregnancy unless potential benefit outweighs risk.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
It is unknown if voclosporin is excreted in human milk. In animal studies, voclosporin and its metabolites were detected in milk of lactating rats. No M/P ratio available for humans. Due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for 4 weeks after last dose.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No specific dose adjustments are established for pregnancy. However, pregnancy can increase voclosporin clearance due to expanded plasma volume and enhanced metabolism. Consider therapeutic drug monitoring if available, and adjust dose to maintain therapeutic trough levels (target 30-60 ng/m L) as needed.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Monitor for hematuria, proteinuria, and e GFR during treatment. Lupkynis (voclosporin) is a calcineurin inhibitor; do not co-administer with other CNIs or strong CYP3A4 inhibitors. Reduce dose in patients with e GFR <45 m L/min per 1.73 m². Concomitant use with mycophenolate mofetil and corticosteroids is standard. Check blood pressure and serum potassium regularly. Live vaccines contraindicated.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,You will need regular blood and urine tests to monitor kidney function and drug levels.,Report any signs of infection (fever, sore throat), high blood pressure (severe headache, vision changes), or changes in urine output/color.,Avoid grapefruit and grapefruit juice during treatment.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 12 weeks after last dose if of childbearing potential.,Tell your doctor about all medications, including over-the-counter drugs and supplements.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUPKYNIS vs INJECTAPAP, answered by our medical review team.
LUPKYNIS is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor immunosuppressant that binds to cyclophilin A, inhibiting calcineurin activity, which prevents dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), thereby reducing cytokine production and T-cell activation.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUPKYNIS and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUPKYNIS is: 23.7 mg orally twice daily with food.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUPKYNIS and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUPKYNIS is classified as Category C. LUPKYNIS (voclosporin) is a calcineurin inhibitor. Based on animal studies, there is a risk of fetal harm in all trimesters. In rats and rabbits, voclosporin administration during . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.